{
  "trial_id": "NCT02049346",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Aged \u226518 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "haemodialysis 3 x week with urea reduction ratio greater or equal to 65% or KT/V ( K - dialyzer clearance of urea, t - dialysis time, V - volume of distribution of urea, approximately equal to patient's total body water) greater or equal to 1.2.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must have received haemodialysis three times weekly for \u226512 weeks before screening and during the 4-week screening/baseline period.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Eligible patients must have stable hemoglobin concentrations (stable is defined as \u226425% change in weekly dose of ESA over 8 weeks).",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Recruited patients must have undergone continuous maintenance intravenous conventional Epoetin alpha or beta therapy for \u22658 weeks before screening and during the screening/baseline.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients should have adequate iron status, defined as serum ferritin \u2265100 \u03bcg/L and transferrin saturation \u226520%.",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "New York Heart Association (NYHA) class III or IV congestive heart failure",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Uncontrolled hypertension (defined as pre-dialysis diastolic blood pressure \u2265105 mmHg or systolic BP\u2265 160 mmHg during the screening period)",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Evidence of uncontrolled hyperparathyroidism (defined as parathyroid hormone level >1000 pg/ml with no response to conventional treatment of hyperparathyroidism according to Kidney Disease Outcomes Quality Initiative (KDOQI) guide line during the 12 months prior to baseline)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Treatment for grand mal epilepsy",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Haematological, inflammatory or infectious conditions that might interfere with the erythropoietin response",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Received red blood cell transfusions within 12 weeks before screening or during the screening/baseline period.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "reactive protein >30 mg/L",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "The likelihood of early withdrawal; or life expectancy of <12 months",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has vomiting, non-bloody diarrhea, abdominal pain, fever, chills and loss of appetite for the past 3 days. He ate a salad at a restaurant prior to his diarrhea onset.",
  "_meta": {
    "topic_id": "32",
    "trial_id": "NCT02049346",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}